India’s first indigenously developed coVID-19 vaccine entered clinical trials Thursday, Hindustan Times reported.
Covaxin, an inactivated vaccine, has recently been approved for clinical trials by India’s Drug Administration.
Phase I trials will be conducted among 375 healthy volunteers aged 18 to 55, of whom about 100 will be tested at the All India Academy of Medical Sciences.
Phase II will involve 750 volunteers aged 12 to 65 from all 12 districts.

Leave a Reply

Your email address will not be published. Required fields are marked *